Workflow
DexCom(DXCM)
icon
Search documents
DXCM INVESTOR NEWS: DexCom, Inc. Investors that Suffered Losses are Encouraged to Contact BFA Law about a Potential Class Action Lawsuit for Securities Fraud (Nasdaq:DXCM)
GlobeNewswire News Room· 2024-08-12 10:11
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...
DXCM INVESTOR ALERT: A Securities Fraud Investigation was Initiated Against DexCom, Inc. (Nasdaq:DXCM); Investors that Lost Money are Encouraged to Contact BFA Law
GlobeNewswire News Room· 2024-08-10 11:36
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...
Investigation Reminder for DexCom Investors: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm
GlobeNewswire News Room· 2024-08-09 22:32
RADNOR, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) (“DexCom”). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that ...
DexCom's Competitive Landscape: A Deep Dive Into The CGM Market
Seeking Alpha· 2024-08-08 13:23
Dragoljub Bankovic Thesis DexCom, Inc. (NASDAQ:DXCM), is a company focused on the development and commercialization of medical devices for continuous glucose measurement (CGM). Late last month, the company reported Q2 earnings, revealing a decline in new customers as well as a decline in U.S. revenue/customer, which triggered the company to decrease their 2024 revenue guidance from $4.2–4.35 billion (17 — 21% organic growth) to $4.0–4.5 billion (11 — 13% organic growth). To balance the guidance update, ...
These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?
The Motley Fool· 2024-08-08 12:45
It might be a great time to buy low.Earnings season can be a volatile time in the stock market. Some corporations produce financial results that are impressive enough to send their share prices soaring, while others move in the exact opposite direction. Medical device specialist DexCom (DXCM -7.88%) and social media platform Pinterest (PINS -0.21%) are in the latter group.Both failed to impress investors with their second-quarter results. DexCom's stock dropped by about 40% in one day, while Pinterest's dec ...
DexCom Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm
Prnewswire· 2024-08-07 13:15
RADNOR, Pa., Aug. 7, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that the c ...
DXCM FRAUD NOTICE: Lose Money on Your DexCom, Inc. Investment? BFA Law is Investigating the Company for Securities Fraud and Urges You to Contact the Firm (NASDAQ:DXCM)
GlobeNewswire News Room· 2024-08-06 11:10
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...
DXCM STOCK NOTICE: DexCom, Inc. is being Investigated for Securities Fraud by BFA Law; Shareholders that Lost Money are Urged to Contact the Firm (NASDAQ:DXCM)
GlobeNewswire News Room· 2024-08-04 10:52
NEW YORK, Aug. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...
Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
MarketBeat· 2024-08-03 11:30
Recently, weight loss and diabetes watch company DexCom Inc. NASDAQ: DXCM stock plummeted by over 44% on a surprisingly bad quarterly earnings report. Management guided lower – much lower – than analysts had expected to see revenue and earnings per share (EPS), and it all had to do with the decreasing demand for the company’s medical devices, which are being replaced more and more by effective medicine lately.Hims & Hers Health TodayHIMSHims & Hers Health$17.56 -0.95 (-5.13%) 52-Week Range$5.65▼$25.74Price ...
DXCM Investors Have Opportunity to Join DexCom, Inc. Securities Fraud Investigation with the Schall Law Firm
Prnewswire· 2024-08-02 13:30
LOS ANGELES, Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. DexCom announced its second quarter earnings on July 25, 2024, including revenue that f ...